160 related articles for article (PubMed ID: 21989411)
21. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
[TBL] [Abstract][Full Text] [Related]
22. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
[TBL] [Abstract][Full Text] [Related]
23. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
24. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer.
Met O; Balslev E; Flyger H; Svane IM
Breast Cancer Res Treat; 2011 Jan; 125(2):395-406. PubMed ID: 20336365
[TBL] [Abstract][Full Text] [Related]
25. Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells.
Papadopoulos KP; Hesdorffer CS; Suciu-Foca N; Hibshoosh H; Harris PE
Clin Cancer Res; 1999 Aug; 5(8):2089-93. PubMed ID: 10473091
[TBL] [Abstract][Full Text] [Related]
26. Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2.
Asemissen AM; Haase D; Stevanovic S; Bauer S; Busse A; Thiel E; Rammensee HG; Keilholz U; Scheibenbogen C
J Immunother; 2009 May; 32(4):370-5. PubMed ID: 19342968
[TBL] [Abstract][Full Text] [Related]
27. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K
Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737
[TBL] [Abstract][Full Text] [Related]
28. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
29. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
30. Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancer.
Forget MA; Reuben A; Turcotte S; Martin J; Lapointe R
Cancer Immunol Immunother; 2011 Aug; 60(8):1119-25. PubMed ID: 21681374
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
[TBL] [Abstract][Full Text] [Related]
32. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
Houbiers JG; Nijman HW; van der Burg SH; Drijfhout JW; Kenemans P; van de Velde CJ; Brand A; Momburg F; Kast WM; Melief CJ
Eur J Immunol; 1993 Sep; 23(9):2072-7. PubMed ID: 8370389
[TBL] [Abstract][Full Text] [Related]
33. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
Dobaño C; Doolan DL
Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
[TBL] [Abstract][Full Text] [Related]
34. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
[TBL] [Abstract][Full Text] [Related]
35. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
36. Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope.
Thorn M; Wang M; Kløverpris H; Schmidt EG; Fomsgaard A; Wenandy L; Berntsen A; Brunak S; Buus S; Claesson MH
Cancer Immunol Immunother; 2007 Nov; 56(11):1755-63. PubMed ID: 17464507
[TBL] [Abstract][Full Text] [Related]
37. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
38. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
Albers AE; Ferris RL; Kim GG; Chikamatsu K; DeLeo AB; Whiteside TL
Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P
Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064
[TBL] [Abstract][Full Text] [Related]
40. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
